Literature DB >> 33717952

Thromboprophylaxis across orthopaedic surgery: Bibliometric analysis of the most cited articles.

Anil Sedani1, Ramakanth Yakkanti2, Paul Allegra2, Lavi Mattingly1, Amiethab Aiyer2.   

Abstract

PURPOSE: One of the most common adverse events after orthopaedic surgery, with a potential for subsequent serious morbidity and mortality is venous thromboembolism (VTE). Bibliometric analysis has been performed regarding many topics and across orthopaedics. As DVT prophylaxis is a major component of both orthopaedic surgery considerations and research, a bibliometric analysis in this area would prove beneficial in not only in understanding the research done in the field thus far, but would also direct future research efforts.
METHODS: The Web of Science (WoS) database from the Institute of Scientific Information (ISI) was used to compile articles for bibliometric analysis using Boolean search: ((Orthopaedic∗ OR Orthopaedic∗) AND (thromboprophylaxis OR Thromboembolism OR Deep vein thrombosis OR thrombus OR embolism OR anticoagulation OR Embolus OR prophylaxis)).
RESULTS: The Top 100 cited articles included in the final list generated a total of 21,099 citations. The highest cited article was Prevention of venous thromboembolism by Geerts et al. published in Chest, which had a total of 2802 on WoS, and a calculated citation density of 215.54 of citations/years since publication. Comparing the overall citation against the year of publication there was a slight positive trend favoring more recent publications (R-value: 0.142; adjusted R-squared: 0.01; p = 0.16). Analysis of an articles Level of Evidence (LOE), 17 were grade with a level of I.
CONCLUSIONS: Orthopaedic thromboprophylaxis is an ever-changing field that is at the forefront of orthopaedic literature. The significant trend favoring high quality research within orthopaedic thromboprophylaxis demonstrates the importance of this topic and there was a need for a guide to best understand the evolution of DVT prophylaxis.
© 2020 Delhi Orthopedic Association. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Bibliometric analysis; Deep vein thrombosis; Pulmonary embolism; Venous thromboprophylaxis

Year:  2021        PMID: 33717952      PMCID: PMC7920107          DOI: 10.1016/j.jcot.2020.12.015

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  66 in total

1.  Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)

Authors:  O E Dahl; G Andreassen; T Aspelin; C Müller; P Mathiesen; S Nyhus; M Abdelnoor; J H Solhaug; H Arnesen
Journal:  Thromb Haemost       Date:  1997-01       Impact factor: 5.249

2.  A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.

Authors:  Alexander G G Turpie; Sylvia Haas; Reinhold Kreutz; Lorenzo G Mantovani; Cassandra W Pattanayak; Gerlind Holberg; Waheed Jamal; André Schmidt; Martin van Eickels; Michael R Lassen
Journal:  Thromb Haemost       Date:  2013-10-24       Impact factor: 5.249

3.  A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.

Authors:  Bengt I Eriksson; Ann-Christin Arfwidsson; Lars Frison; Ulf G Eriksson; Anders Bylock; Peter Kälebo; Gunnar Fager; David Gustafsson
Journal:  Thromb Haemost       Date:  2002-02       Impact factor: 5.249

4.  Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery.

Authors:  Clifford W Colwell; Lewis M Kwong; Alexander G G Turpie; Bruce L Davidson
Journal:  J Arthroplasty       Date:  2006-01       Impact factor: 4.757

5.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors:  B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

6.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

Review 7.  State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis.

Authors:  Russell D Hull; Roger D Yusen; David Bergqvist
Journal:  Clin Appl Thromb Hemost       Date:  2009-07-15       Impact factor: 2.389

8.  Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Authors:  Bengt I Eriksson; Lars C Borris; Richard J Friedman; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Tiemo J Bandel; Horst Beckmann; Eva Muehlhofer; Frank Misselwitz; William Geerts
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

9.  Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

Authors:  Wolfgang Mueck; Bengt I Eriksson; Kenneth A Bauer; Lars Borris; Ola E Dahl; William D Fisher; Michael Gent; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Orthopaedic Academic Activity in the United States: Bibliometric Analysis of Publications by City and State.

Authors:  Erik Hohmann; Vaida Glatt; Kevin Tetsworth
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2018-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.